Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
Morille, M.
Montier, T.
Legras, P.
Carmoy, N.
Brodin, P.
Pitard, B.
Benoit, J. P.
Passirani, C.
Biomaterials, 2010
Jean-Pierre BENOIT
BENOIT Jean-Pierre
ORCID: 0000-0002-6178-7199
The advantages of nanomedicine in the treatment of visceral Leishmaniasis: between sound arguments and wishful thinking.
10.1080/17425247.2021.1853701
Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer.
10.1021/acsami.0c05554
Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery.
10.1016/j.ejpb.2020.02.008
Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.
10.1186/s12951-020-00589-3
Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?
10.1016/j.actatropica.2019.105215
Self-assembled hyaluronan nanocapsules for the intracellular delivery of anticancer drugs.
10.1038/s41598-019-47995-8
Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency.
10.2217/nnm-2019-0059
The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
10.1186/s40425-019-0536-x
Albendazole-lipid nanocapsules: Optimization, characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus.
10.1016/j.exppara.2019.02.002
Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules.
10.1080/1061186x.2018.1547733
Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters.
10.1016/j.ejpb.2018.11.020
Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications.
10.1016/j.ijpharm.2019.118795
In vitro anti-cancer activity and pharmacokinetic evaluation of curcumin-loaded lipid nanocapsules.
10.1016/j.msec.2018.06.014
Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats.
10.2147/ijn.s146740
Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?
10.1016/j.jconrel.2017.09.031
Experimental cystic echinococcosis therapy: In vitro and in vivo combined 5-fluorouracil/albendazole treatment.
10.1016/j.vetpar.2017.08.011
Ivermectin lipid-based nanocarriers as novel formulations against head lice.
10.1007/s00436-017-5510-2
Cytotoxicity and genotoxicity of lipid nanocapsules.
10.1016/j.tiv.2017.03.007
Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model.
10.1016/j.jconrel.2017.03.005
Stealth nanocarriers based sterosomes using PEG post-insertion process.
10.1016/j.ejpb.2017.02.008
Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse.
10.1016/j.phrs.2017.01.031
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
10.1016/j.biomaterials.2016.04.010
How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?
10.1016/j.addr.2016.03.011
An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors.
10.1038/srep21417
Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications.
10.1007/s00436-016-4937-1
Inter-nanocarrier and nanocarrier-to-cell transfer assays demonstrate the risk of an immediate unloading of dye from labeled lipid nanocapsules.
10.1016/j.ejpb.2015.10.011
Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma.
10.1016/j.ijpharm.2015.09.062
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice.
10.1016/j.actatropica.2015.09.016
Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice.
10.1016/j.nano.2015.02.010
In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.
10.2217/nnm.14.124
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
10.1016/j.ijpharm.2015.01.051
Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
10.1002/biot.201400162
FRET imaging approaches for in vitro and in vivo characterization of synthetic lipid nanoparticles.
10.1021/mp500329z
In vitro effect of 5-fluorouracil and paclitaxel on Echinococcus granulosus larvae and cells.
10.1016/j.actatropica.2014.07.013
Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring.
10.1016/j.jconrel.2014.05.042
Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules.
10.1016/j.nano.2014.05.002
Impact of interfacial cholesterol-anchored polyethylene glycol on sterol-rich non-phospholipid liposomes.
10.1016/j.jcis.2014.04.031
Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.
10.2147/ijn.s59134
An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure.
10.1039/c3sm52781f
Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency.
10.2217/nnm.13.205
Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel.
10.1016/j.ejpb.2014.02.004
Tumour targeting of lipid nanocapsules grafted with cRGD peptides.
10.1016/j.ejpb.2013.12.006
Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.
10.2147/ijn.s51837
In vivo evaluation of poly-l-asparagine nanocapsules as carriers for anti-cancer drug delivery.
10.1016/j.ijpharm.2013.09.038
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide.
10.1016/j.ejps.2013.06.013
A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging.
10.1016/j.jconrel.2013.06.014
Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells.
10.1016/j.ijpharm.2013.06.013
Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting.
10.1016/j.ijpharm.2013.05.057
A review of the current status of siRNA nanomedicines in the treatment of cancer.
10.1016/j.biomaterials.2013.04.060
EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro.
10.1016/j.ijpharm.2013.04.001
Surface modification of lipid nanocapsules with polysaccharides: from physicochemical characteristics to in vivo aspects.
10.1016/j.actbio.2013.01.038
The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells.
10.1016/j.biomaterials.2013.01.068
Perfluorocarbon-loaded lipid nanocapsules as oxygen sensors for tumor tissue pO₂ assessment.
10.1016/j.ejpb.2013.01.003
DNA nanocarriers for systemic administration: characterization and in vivo bioimaging in healthy mice.
10.1038/mtna.2012.56
Aqueous core nanocapsules: a new solution for encapsulating doxorubicin hydrochloride.
10.3109/03639045.2012.730526
Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model.
10.1002/jgm.2683
Relationship between affective symptoms and malnutrition severity in severe Anorexia Nervosa.
10.1371/journal.pone.0049380
Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.
10.1021/mp300370t
Smart nanocarriers for pH-triggered targeting and release of hydrophobic drugs.
10.1016/j.actbio.2012.08.049
Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models.
10.1016/j.nano.2012.08.005
Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
10.1099/jmm.0.042739-0
Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride.
10.1016/j.ijpharm.2012.06.026
Evaluation of surface deformability of lipid nanocapsules by drop tensiometer technique, and its experimental assessment by dialysis and tangential flow filtration.
10.1016/j.ijpharm.2012.06.019
Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules.
10.1016/j.ejpb.2012.04.012
siRNA LNCs--a novel platform of lipid nanocapsules for systemic siRNA administration.
10.1016/j.ejpb.2012.02.010
Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative.
10.1016/j.ijpharm.2012.01.038
[Conception and studies of micro and nanomedicines for brain applications].
10.1051/jbio/2012026
Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells.
10.1007/s11095-011-0624-1
In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expression.
10.3892/ijo.2011.1271
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.
10.2147/ijn.s25791
Protein-loaded PLGA-PEG-PLGA microspheres: a tool for cell therapy.
10.1016/j.ejps.2011.10.030
The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells.
10.1371/journal.pone.0025515
Passive and active tumour targeting with nanocarriers.
10.2174/157016311796798991
Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles.
10.1016/j.biomaterials.2011.07.057
OPA quantification of amino groups at the surface of lipidic nanocapsules (LNCs) for ligand coupling improvement.
10.1016/j.ijpharm.2011.07.028
A starch-based microparticulate system dedicated to diagnostic and therapeutic nuclear medicine applications.
10.1016/j.biomaterials.2011.07.007
Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules.
10.1016/j.biomaterials.2011.05.067
In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model.
10.1016/j.ijpharm.2011.06.031
Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect.
10.1007/s11095-011-0501-y
Stealth properties of poly(ethylene oxide)-based triblock copolymer micelles: a prerequisite for a pH-triggered targeting system.
10.1016/j.actbio.2011.06.014
Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133.
10.1016/j.ijpharm.2011.06.001
Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma.
10.1016/j.ijpharm.2011.04.037
Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model.
10.1371/journal.pone.0016926
Reverse micelle-loaded lipid nanocarriers: a novel drug delivery system for the sustained release of doxorubicin hydrochloride.
10.1016/j.ejpb.2011.02.015
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration.
10.1016/j.ejpb.2011.01.021
Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy?
10.1016/j.ijpharm.2011.01.027
Tumor transfection after systemic injection of DNA lipid nanocapsules.
10.1016/j.biomaterials.2010.11.063
Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1.
10.1016/j.jconrel.2010.11.032
The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
10.2217/nnm.10.113
Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.
10.1016/j.ijpharm.2010.10.015
Local implantation of doxorubicin drug eluting beads in rat glioma.
10.1016/j.ijpharm.2010.09.013
Methods for the functionalisation of nanoparticles: new insights and perspectives.
10.1002/chem.201000808
Reverse micelle-loaded lipid nano-emulsions: new technology for nano-encapsulation of hydrophilic materials.
10.1016/j.ijpharm.2010.07.039
Layer-by-layer surface modification of lipid nanocapsules.
10.1016/j.ejpb.2010.07.010
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability.
10.1016/j.biomaterials.2010.06.024
Post-insertion into Lipid NanoCapsules (LNCs): From experimental aspects to mechanisms.
10.1016/j.ijpharm.2010.06.019
Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.
10.1016/j.ejps.2010.04.015
Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique.
10.1016/j.ejpb.2010.03.005
Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.
10.1007/s11095-009-0024-y
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
10.2217/nnm.09.110
New starch-based radiotracer for lung perfusion scintigraphy.
10.1007/s00259-009-1226-6
Non-viral nanosystems for systemic siRNA delivery.
10.1016/j.phrs.2009.11.013
Adult cell therapy for brain neuronal damages and the role of tissue engineering.
10.1016/j.biomaterials.2009.11.084
Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft.
10.1007/s11095-009-0006-0
Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers.
10.1007/s11095-009-9986-z
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules.
10.1021/la901565q
In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy.
10.1007/s11060-009-0012-4
Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis.
10.1016/j.jconrel.2009.08.010
Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
10.1016/j.ejpb.2009.06.013
The gastrointestinal stability of lipid nanocapsules.
10.1016/j.ijpharm.2009.05.069
Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting.
10.1016/j.ijpharm.2009.05.065
Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model.
10.1016/j.ijpharm.2009.05.031
The adaptation of lipid nanocapsule formulations for blood administration in animals.
10.1016/j.ijpharm.2009.05.033
Interactions between poly(ethylene glycol) and protein in dichloromethane/water emulsions. 2. Conditions required to obtain spontaneous emulsification allowing the formation of bioresorbable poly(D,L lactic acid) microparticles.
10.1016/j.ejpb.2009.04.011
Lipid nanocapsules: a new platform for nanomedicine.
10.1016/j.ijpharm.2009.04.026
The encapsulation of DNA molecules within biomimetic lipid nanocapsules.
10.1016/j.biomaterials.2009.03.009
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.
10.1016/j.biomaterials.2009.01.003
Imaging E-selectin expression following traumatic brain injury in the rat using a targeted USPIO contrast agent.
10.1007/s10334-008-0161-z
Synthesis and pH-dependent micellization of diblock copolymer mixtures.
10.1016/j.jcis.2008.09.080
Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas.
10.1016/j.jconrel.2008.05.027
[Local chemotherapy of malignant glioma: from syringe injections to nanotechnology].
10.1016/j.neurol.2008.03.015
[Oral bioavailability and drug/carrier particulate systems].
10.1051/medsci/20082467659
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer.
10.1016/j.biomaterials.2008.04.036
188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas.
10.1007/s00259-008-0735-z
Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres.
10.1016/j.ejpb.2008.03.006
Design and production of nanoparticles formulated from nano-emulsion templates-a review.
10.1016/j.jconrel.2008.02.007
Interactions between poly(ethylene glycol) and protein in dichloromethane/water emulsions: a study of interfacial properties.
10.1016/j.ejpb.2008.01.021
Lipid nanocapsules for intracellular drug delivery of anticancer drugs.
10.1166/jnn.2007.18114
How to achieve sustained and complete protein release from PLGA-based microparticles?
10.1016/j.ijpharm.2007.11.012
Brain targeting using novel lipid nanovectors.
10.1016/j.jconrel.2007.11.001
Active targeting of brain tumors using nanocarriers.
10.1016/j.biomaterials.2007.06.011
Perfusional deficit and the dynamics of cerebral edemas in experimental traumatic brain injury using perfusion and diffusion-weighted magnetic resonance imaging.
10.1089/neu.2006.0136
The influence of headgroup structure and fatty acyl chain saturation of phospholipids on monolayer behavior: a comparative rheological study.
10.1016/j.chemphyslip.2007.06.226
In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel.
10.1016/j.ijpharm.2007.06.014
5-ASA loaded chitosan-Ca-alginate microparticles: Preparation and physicochemical characterization.
10.1016/j.ijpharm.2007.05.059
Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments.
10.1016/j.biomaterials.2007.05.014
Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion.
10.1016/j.ijpharm.2007.04.027
Salting-out effect induced by temperature cycling on a water/nonionic surfactant/oil system.
10.1021/jp0664768
Evaluating SPIO-labelled cell MR efficiency by three-dimensional quantitative T2* MRI.
10.1002/nbm.1084
Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats.
10.1016/j.biomaterials.2006.12.021
Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma.
10.3171/jns.2006.105.5.745
Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification.
10.1080/03639040600683501
Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake.
10.1002/jbm.a.30711
Pegylated nanocapsules produced by an organic solvent-free method: Evaluation of their stealth properties.
10.1007/s11095-006-9061-y
A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats.
10.1158/1535-7163.mct-06-0289
The brain tissue response to biodegradable poly(methylidene malonate 2.1.2)-based microspheres in the rat.
10.1016/j.biomaterials.2006.04.045
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
10.1007/s11095-006-0022-2
Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent.
10.1016/j.ijpharm.2006.04.007
Parameters influencing the stealthiness of colloidal drug delivery systems.
10.1016/j.biomaterials.2006.03.039
Development and characterization of interleukin-18-loaded biodegradable microspheres.
10.1016/j.ijpharm.2005.07.029
In vitro investigation of lipid implants as a controlled release system for interleukin-18.
10.1016/j.ijpharm.2005.08.031
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition.
10.1016/j.jconrel.2006.02.014
Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.
10.1016/j.ijpharm.2005.07.030
Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts.
10.1016/j.ejpb.2005.11.006
Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization.
10.1016/j.ijpharm.2005.07.028
Novel composite core-shell nanoparticles as busulfan carriers.
10.1016/j.jconrel.2006.01.002
Dynamics of cerebral edema and the apparent diffusion coefficient of water changes in patients with severe traumatic brain injury. A prospective MRI study.
10.1007/s00330-005-0086-0
99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution.
10.1007/s00259-005-0007-0
Development of new polymer-based particulate systems for anti-glioma vaccination.
10.1016/j.ijpharm.2005.10.046
Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.
10.1007/s11095-005-7147-6
Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants.
10.1016/j.biomaterials.2005.04.004
Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat.
10.1258/0023677054307051
Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model.
10.1016/j.ijpharm.2005.03.025
Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation.
10.1016/j.ejpb.2005.04.004
Effect of stabilized iodized oil emulsion on experimentally induced hepatocellular carcinoma in rats.
10.1097/01.rvi.0000156192.89569.0c
Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface.
10.1002/elps.200410145
Pharmacologically active microcarriers: a tool for cell therapy.
10.1016/j.biomaterials.2004.09.042
Interactions between hen egg-white lysozyme, PEG2,000, and PLA50 at the air-water interface.
10.1016/j.colsurfb.2005.02.003
Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model.
10.1016/j.ejpb.2004.08.013
Drug delivery into the brain using poly(lactide-co-glycolide) microspheres.
10.1517/17425247.2.2.363
Combining polymeric devices and stem cells for the treatment of neurological disorders: a promising therapeutic approach.
10.2174/1389450053344885
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial.
10.1227/01.neu.0000144982.82068.a2
Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent.
10.1007/s11095-004-7693-3
188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma.
10.1097/00006231-200410000-00004
Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization.
10.1023/b:pham.0000041448.22771.48
Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment.
10.1016/j.ijpharm.2004.03.018
Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats.
10.1016/j.neulet.2004.02.068
Effect of the size of biodegradable microparticles on drug release: experiment and theory.
10.1016/j.jconrel.2004.01.011
In vitro study of GDNF release from biodegradable PLGA microspheres.
10.1016/j.jconrel.2003.12.012
Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers.
10.1016/s0939-6411(03)00146-2
Pitfalls in the detection of lipid vectors in neural cell culture and in brain tissue.
10.1002/jbm.a.20060
Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease.
10.1016/s0142-9612(03)00601-x
Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
10.1016/j.neulet.2003.11.051
Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes.
10.1016/j.jconrel.2003.10.024
In vivo evaluation of pharmacologically active microcarriers releasing nerve growth factor and conveying PC12 cells.
10.3727/000000004783983675
Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma.
10.1002/cncr.11922
Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma.
10.1016/j.ijpharm.2003.08.014
Physico-chemical stability of colloidal lipid particles.
10.1016/s0142-9612(03)00331-4
Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation.
10.1016/s0939-6411(03)00104-8
Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility.
10.1016/s0142-9612(03)00161-3
Spectroscopic studies on poly(ethylene glycol)-lysozyme interactions.
10.1016/s0378-5173(03)00258-8
Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats.
10.1002/cncr.11388
Simple liquid-chromatographic method for Nile Red quantification in cell culture in spite of photobleaching.
10.1016/s1570-0232(02)00962-5
Interfacial properties of adsorbed films made of a PEG2000 and PLA50 mixture or a copolymer at the dichloromethane-water interface.
10.1016/s0021-9797(02)00235-7
The influence of lipid nanocapsule composition on their size distribution.
10.1016/s0928-0987(02)00241-5
A supercritical fluid-based coating technology. 3: preparation and characterization of bovine serum albumin particles coated with lipids.
10.1080/02652040210162630
A supercritical fluid-based coating technology. 2: solubility considerations.
10.1080/02652040210162649
A supercritical fluid-based coating technology 1: process considerations.
10.3109/02652040309178051
Implantable drug-releasing biodegradable microspheres for local treatment of brain glioma.
10.1007/978-3-7091-6090-9_9
A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations.
10.1023/a:1021457911533
New lipid nanocapsules exhibit sustained release properties for amiodarone.
10.1016/s0168-3659(02)00258-4
Influence of some formulation parameters on lysozyme adsorption and on its stability in solution.
10.1016/s0378-5173(02)00226-0
Properties of polyethylene glycol 660 12-hydroxy stearate at a triglyceride/water interface.
10.1016/s0378-5173(02)00144-8
Microencapsulation of protein particles within lipids using a novel supercritical fluid process.
10.1016/s0378-5173(02)00149-7
A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres.
10.1023/a:1016482809810
A quantitative method for the determination of amphiphilic drug release kinetics from nanoparticles using a Langmuir balance.
10.1021/ac025581k
A novel phase inversion-based process for the preparation of lipid nanocarriers.
10.1023/a:1016121319668
Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
10.1002/syn.10063
PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release.
10.1016/s0928-0987(02)00023-4
Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres.
10.1016/s0939-6411(02)00011-5
Development and characterization of solid lipid nanoparticles loaded with magnetite.
10.1016/s0378-5173(01)00936-x
Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study.
10.1002/nbm.720
Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy.
10.3171/jns.2001.95.3.0489
PLGA microsphere bioburden evaluation for radiosterilization dose selection.
10.1080/02652040010019424
Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons.
10.1016/s0142-9612(00)00141-1
Development of microspheres for neurological disorders: from basics to clinical applications.
10.1016/s0168-3659(99)00250-3
Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.
10.1006/exnr.1999.7253
Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres?
10.1023/a:1014818118224
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study.
10.1002/(sici)1097-0142(19990715)86:2<325::aid-cncr17>3.0.co;2-s
Modulated release of IdUrd from poly (D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers.
10.1016/s0168-3659(98)00165-5
Rhizobacteria microencapsulation: properties of microparticles obtained by spray-drying.
10.1080/026520499289194
Development of 5-iodo-2'-deoxyuridine milling process to reduce initial burst release from PLGA microparticles.
10.1016/s0378-5173(98)00380-9
Direct qualitative and quantitative characterization of a radiosensitizer, 5-iodo-2'-deoxyuridine within biodegradable polymeric microspheres by FT-Raman spectroscopy.
10.1039/a806678g
The characterization and release kinetics evaluation of baclofen microspheres designed for intrathecal injection.
10.1016/s0378-5173(98)00350-0
NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability.
10.1016/s0168-3659(98)00086-8
Microencapsulation of rhizobacteria by spray-drying: formulation and survival studies.
10.3109/02652049809008247
Physical aging of progesterone-loaded poly(D,L,-lactide-co-glycolide) microspheres.
10.1023/a:1011991624411
Internal morphology of poly(D,L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability.
10.1016/s0939-6411(97)00120-3
Tensioactivity and supramolecular organization of the palmitoyl prodrug of timolol.
10.1023/a:1012047231989
Surface characterization of poly(alpha-hydroxy acid) microspheres prepared by a solvent evaporation/extraction process.
10.1016/s0142-9612(96)00102-0
Preparation, purification and morphology of polymeric nanoparticles as drug carriers.
10.1016/0031-6865(95)00059-3
Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats.
10.1097/00006123-199607000-00023
Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure.
10.3109/02652049609006802
Diffuse scattering in protein crystallography.
10.1017/s0033583500003048
Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers.
10.1111/j.2042-7158.1995.tb05760.x
In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.
10.3109/10611869509015929
Fate and biocompatibility of three types of microspheres implanted into the brain.
10.1002/jbm.820280913
Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres.
10.1227/00006123-199406000-00016
End-chain radiolabeling and in vitro stability studies of radiolabeled poly(hydroxy acid) nanoparticles.
10.1002/jps.2600830618
Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres.
10.1016/0142-9612(93)90151-q
Preliminary evaluation of a series of amphiphilic timolol prodrugs: possible evidence for transscleral absorption.
10.1089/jop.1993.9.141
Ibuprofen-loaded ethylcellulose microspheres: analysis of the matrix structure by thermal analysis.
10.1002/jps.2600801106
A physicochemical study of the morphology of progesterone-loaded microspheres fabricated from poly(D,L-lactide-co-glycolide).
10.1002/jbm.820250509
Ibuprofen-loaded ethylcellulose microspheres: release studies and analysis of the matrix structure through the Higuchi model.
10.3109/02652049009040479
Influence of average molecular weights of poly(DL-lactic acid-co-glycolic acid) copolymers 50/50 on phase separation and in vitro drug release from microspheres.
10.1023/a:1015945806917
In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method.
10.1016/0142-9612(89)90063-x
In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: a diglyceride prodrug.
10.1111/j.2042-7158.1989.tb06428.x
Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases.
10.1089/sct.1989.5.1
Ion-exchange albumin microcapsules of doxorubicin: an in vitro release kinetic evaluation.
10.3109/02652048809064170
Magnetically responsive microspheres for the pulsed delivery of insulin.
10.1016/0024-3205(88)90009-4
Binding mechanism of doxorubicin in ion-exchange albumin microcapsules.
10.1002/jps.2600760613
Calcium and thiocyanate interactions with crosslinked albumin microcapsules: influence of the reticulation rate.
10.1016/0142-9612(87)90066-4
5-Fluorouracil:carnauba wax microspheres for chemoembolization: an in vitro evaluation.
10.1002/jps.2600750905
Formation and characterization of cisplatin loaded poly(d,l-lactide) microspheres for chemoembolization.
10.1002/jps.2600750805
The formation and characterization of hydrocortisone-loaded poly((+/-)-lactide) microspheres.
10.1111/j.2042-7158.1986.tb04561.x
Characterization of drug-loaded poly(d,l-lactide) microspheres.
10.1002/jps.2600731215
Biodegradable cross-linked albumin microcapsules for embolization.
10.3109/02652048409031544
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
Marie Morille
Morille Marie
ORCID: 0000-0001-8224-7346
Liposomes, lipid nanocapsules and smartCrystals®: A comparative study for an effective quercetin delivery to the skin
10.1016/j.ijpharm.2018.03.019
Tripartite polyionic complex (PIC) micelles as non-viral vectors for mesenchymal stem cell siRNA transfection
10.1039/c7bm00384f
Dermal quercetin lipid nanocapsules: Influence of the formulation on antioxidant activity and cellular protection against hydrogen peroxide
10.1016/j.ijpharm.2016.12.043
Quercetin topical application, from conventional dosage forms to nanodosage forms
10.1016/j.ejpb.2016.08.011
Non-viral gene activated matrices for mesenchymal stem cells based tissue engineering of bone and cartilage
10.1016/j.biomaterials.2016.07.017
Dermal quercetin smartCrystals®: Formulation development, antioxidant activity and cellular safety
10.1016/j.ejpb.2016.03.004
PLGA-based microcarriers induce mesenchymal stem cell chondrogenesis and stimulate cartilage repair in osteoarthritis
10.1016/j.biomaterials.2016.02.022
Scaffolds for controlled release of cartilage growth factors
10.1007/978-1-4939-2938-2_12
New PLGA-P188-PLGA matrix enhances TGF-β3 release from pharmacologically active microcarriers and promotes chondrogenesis of mesenchymal stem cells
10.1016/j.jconrel.2013.04.017
DNA nanocarriers for systemic administration: Characterization and in vivo bioimaging in healthy mice
10.1038/mtna.2012.56
Near-infrared optical imaging of nucleic acid nanocarriers in vivo
10.1007/978-1-62703-140-0_5
Implication of oxidative stress in size-dependent toxicity of silica nanoparticles in kidney cells
10.1016/j.tox.2012.05.010
Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells
10.1007/s11095-011-0624-1
Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect
10.1007/s11095-011-0501-y
Stealth properties of poly(ethylene oxide)-based triblock copolymer micelles: A prerequisite for a pH-triggered targeting system
10.1016/j.actbio.2011.06.014
Tumor transfection after systemic injection of DNA lipid nanocapsules
10.1016/j.biomaterials.2010.11.063
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting
10.1016/j.ijpharm.2009.05.065
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer
10.1016/j.biomaterials.2008.04.036
Elaboration of materials with functionality gradients by assembly of chitosan-collagen microspheres produced by microfluidics
10.7569/JRM.2017.634186
Fluorescent Biosensor for Detection of the R248Q Aggregation‐Prone Mutant of p53
{10.1002/cbic.201800531}
Polyoxazolines based lipid nanocapsules for topical delivery of antioxidants
10.1016/j.ijpharm.2020.119126
Post-production modifications of murine mesenchymal stem cell (mMSC) derived extracellular vesicles (EVs) and impact on their cellular interaction
10.1016/j.biomaterials.2019.119675
Polyoxazolines based mixed micelles as PEG free formulations for an effective quercetin antioxidant topical delivery
10.1016/j.ijpharm.2019.118516
Near-Infrared Optical Imaging of Nucleic Acid Nanocarriers In Vivo
10.1007/978-1-4939-9092-4_23
PySHS: Python Open Source Software for Second Harmonic Scattering
10.1021/acs.jcim.0c00789
Degradable double hydrophilic block copolymers and tripartite polyionic complex micelles thereof for small interfering ribonucleic acids (siRNA) delivery
10.1016/j.jcis.2020.07.057
Exosomal melanotransferrin as a potential biomarker for metastatic melanoma
10.1101/2020.11.09.373852
Nanotechnologies for Intracellular Protein Delivery: Recent Progress in Inorganic and Organic Nanocarriers
10.1002/adtp.202100009
Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery
10.1016/j.addr.2021.113837
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection.
10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis.
10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces.
10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR.
10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce.
10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens.
10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water.
10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries.
10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment.
10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.
10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system.
10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis.
10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.
10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages.
10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis.
10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs.
10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.
10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.
10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization.
10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro.
10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin].
10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.
10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges].
10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways.
10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence.
10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings.
10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
10.1371/journal.pone.0026675
High-content screening in infectious diseases.
10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling.
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ.
10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure.
10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity.
10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans].
10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.
10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence.
10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine.
10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity.
10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics.
10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6.
10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex.
10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.
10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
